Alveolar type II cell innate immune response to influenza

肺泡 II 型细胞对流感的先天免疫反应

基本信息

  • 批准号:
    7787530
  • 负责人:
  • 金额:
    $ 43.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-01 至 2014-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The alveolar epithelium is the site of infection for many emerging viral infections. Alveolar type II cells produce pulmonary surfactant, are the progenitor cells for the type I alveolar epithelial cells, and pump sodium from the alveolar fluid into the interstitium to prevent alveolar flooding. Alveolar epithelial cells also have the ability to initiate both innate and adaptive immune responses. We have shown that human type II cells produce large amounts of IL-29 (interferon ?), a type III interferon, and CXCL10 (IP-10) and CXCL11 (I- TAC), which are important cytokines for initiating the adaptive immune response, as well as a variety of other cytokines in response to influenza. In this application we will determine the regulation of the antiviral interferon response with a focus on IL-29 and the cytokine inflammatory response with a focus on CXCL10, CXCL11, RANTES, and IL-6. We will also determine the role of surfactant protein D (SP-D) in the innate immune response to influenza and its ability to enhance clearance of viral infected apoptotic cells to limit the spread of infection. We believe that SP-D will be very important in alveolar defense against influenza. In addition we will determine if these processes are altered in two susceptible populations, the elderly and current cigarette smokers. Finally we will begin to determine if these responses are regulated by the virus itself by comparing the effects of contemporary circulating viruses to avian influenza and by the presence or absence of the NS-1 gene in the A/PR/8/34 (H1N1) virus. These studies should highlight two new understudied potential therapeutic targets, (i.e., IL-29 and clearance of apoptotic virally infected cells), and provide more insight into the cells that are actually infected in influenza pneumonia. These studies could be easily expanded in the future to other emerging infections after influenza that cause pneumonia or to the pathogenesis of secondary bacterial infections in collaboration with other IMVC awardees.
描述(由申请人提供):肺泡上皮是许多新出现的病毒感染的部位。肺泡II型细胞产生肺表面活性物质,是I型肺泡上皮细胞的前体细胞,并将肺泡液中的钠泵入间质以防止肺泡溢液。肺泡上皮细胞还具有启动先天和获得性免疫反应的能力。我们已经证明,人类II型细胞产生大量的IL-29(干扰素?),一种III型干扰素,以及CXCL10(IP-10)和CXCL11(I-TAC),这是启动适应性免疫反应的重要细胞因子,以及各种其他细胞因子对流感的反应。在本应用中,我们将以IL-29和细胞因子炎症反应为重点,以CXCL10、CXCL11、RANTES和IL-6为重点,确定抗病毒干扰素反应的调节。我们还将确定表面活性蛋白D(SP-D)在流感先天免疫反应中的作用,以及它增强清除病毒感染的凋亡细胞以限制感染传播的能力。我们认为SP-D在预防流感的肺泡防御中起着非常重要的作用。此外,我们将确定这些过程是否会在两个易感人群中发生变化,即老年人和目前吸烟的人。最后,我们将开始通过比较当代流行病毒对禽流感的影响以及A/PR/8/34(H1N1)病毒中是否存在NS-1基因来确定这些反应是否由病毒本身调节。这些研究应该突出两个新的未被研究的潜在治疗靶点(即IL-29和清除凋亡的病毒感染细胞),并为流感肺炎中实际感染的细胞提供更多洞察。这些研究将来可以很容易地扩展到流感后引起肺炎的其他新出现的感染,或者与其他IMVC获奖者合作,研究继发性细菌感染的发病机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT James MASON其他文献

ROBERT James MASON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT James MASON', 18)}}的其他基金

Air/liquid interface cultures for alveolar type II cell differentiation
用于肺泡 II 型细胞分化的空气/液体界面培养物
  • 批准号:
    8191639
  • 财政年份:
    2011
  • 资助金额:
    $ 43.84万
  • 项目类别:
Air/liquid interface cultures for alveolar type II cell differentiation
用于肺泡 II 型细胞分化的空气/液体界面培养物
  • 批准号:
    8279217
  • 财政年份:
    2011
  • 资助金额:
    $ 43.84万
  • 项目类别:
Alveolar type II cell innate immune response to influenza
肺泡 II 型细胞对流感的先天免疫反应
  • 批准号:
    8074270
  • 财政年份:
    2009
  • 资助金额:
    $ 43.84万
  • 项目类别:
Alveolar type II cell innate immune response to influenza
肺泡 II 型细胞对流感的先天免疫反应
  • 批准号:
    8063939
  • 财政年份:
    2009
  • 资助金额:
    $ 43.84万
  • 项目类别:
Alveolar type II cell innate immune response to influenza
肺泡 II 型细胞对流感的先天免疫反应
  • 批准号:
    8260411
  • 财政年份:
    2009
  • 资助金额:
    $ 43.84万
  • 项目类别:
Alveolar type II cell innate immune response to influenza
肺泡 II 型细胞对流感的先天免疫反应
  • 批准号:
    7679879
  • 财政年份:
    2009
  • 资助金额:
    $ 43.84万
  • 项目类别:
Alveolar type II cell innate immune response to influenza
肺泡 II 型细胞对流感的先天免疫反应
  • 批准号:
    8456892
  • 财政年份:
    2009
  • 资助金额:
    $ 43.84万
  • 项目类别:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
DE PEDIATRIC COBRE:细胞科学核心
  • 批准号:
    7720949
  • 财政年份:
    2008
  • 资助金额:
    $ 43.84万
  • 项目类别:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
DE PEDIATRIC COBRE:细胞科学核心
  • 批准号:
    7610721
  • 财政年份:
    2007
  • 资助金额:
    $ 43.84万
  • 项目类别:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
DE PEDIATRIC COBRE:细胞科学核心
  • 批准号:
    7382170
  • 财政年份:
    2006
  • 资助金额:
    $ 43.84万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 43.84万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 43.84万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 43.84万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 43.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 43.84万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 43.84万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 43.84万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 43.84万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 43.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 43.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了